Reinhard Gabathuler
biOasis Technologies Inc., Canada
Biography
Gabathuler obtained his PhD in Plant Biochemistry at the Université de Lausanne, Switzerland, in 1982, and completed postdoctoral studies at the University of Washington, Seattle. Over the years, he has held various research positions at the Swiss Institute for Experimental Cancer Research, Lausanne; the Ludwig Institute for Cancer Research at the Karolinska Institutet, Stockholm, Sweden; and the Biotechnology Laboratory of the University of British Columbia, Vancouver, Canada. His research on new vector for delivery of therapeutics to the brain led to the creation of Synapse Technologies Inc., where he began as Vice-President Research (1998). The company was later acquired by BioMarin Pharmaceutical Inc., where Dr Gabathuler assumed the position of Vice President of Brain Research (2002). Dr Gabathuler joined AngioChem Inc. in 2005 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company’s product ANG1005 to IND application and clinic. He joined biOasis Technologies Inc. in 2010 as its Chief Scientist, the company is developing a new peptide vector, Transcend (MTf, p97) and its second generation the MTfpep, for the brain delivery of biologics. Since 2013 he is also the President of a new biotechnology company, bioMmune Technologies Inc., concerned with the discovery and development of new therapeutics to restore immune-recognition of tumor cells and to modulate the activity of the immune system.